<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191395</url>
  </required_header>
  <id_info>
    <org_study_id>P/2019/433</org_study_id>
    <nct_id>NCT04191395</nct_id>
  </id_info>
  <brief_title>Evolution and Treatments of Chronic Inflammatory Systemic Diseases</brief_title>
  <acronym>MISTIC</acronym>
  <official_title>Evolution and Treatments of Chronic Inflammatory Systemic Diseases: Implementation of a Hospital Cohort in the Gastroenterology and Rheumatology Departments of the University Hospital of Besançon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic inflammatory diseases (CID) followed in gastroenterology and
      rheumatology have physiopathological, epidemiological and therapeutic focal points. The
      pathologies concerned are inflammatory bowel diseases (IBD - Crohn's disease [MC] and
      ulcerative colitis [RCH]), and chronic inflammatory rheumatic diseases (rheumatoid arthritis
      [RA] and spondyloarthritis [SpA] including psoriatic arthritis [PsA]). Presenting one of
      these diseases is associated with a higher risk of having a second inflammatory pathology,
      whether the latter is ophthalmological, dermatological, rheumatological or
      gastroenterological. An association of extra-articular manifestations is observed in 10 to
      30% of patients with SpA, and an association of extra-intestinal manifestations is observed
      in approximately 30% of patients with IBD. No common database for chronic systemic
      inflammatory diseases currently exists in France.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2019</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis of a second inflammatory disease</measure>
    <time_frame>through study completion (up to 10 years)</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Crohn Disease</condition>
  <condition>Arthritis, Rheumatoid</condition>
  <condition>Spondyloarthritis</condition>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Inflammatory bowel disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic inflammatory rheumatic disease</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Inflammatory Bowel Disease or Chronic inflammatory rheumatic disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients treated for IBD (MC, UC or indeterminate colitis) in the gastroenterology
             department of Besançon University Hospital

          -  Subject meeting the clinical, morphological and histological diagnostic criteria for
             MC, UC or indeterminate colitis or

          -  Patients treated for chronic inflammatory rheumatism (RA, SpA, PsA) in the
             rheumatology department of the University Hospital of Besançon Subject meeting the ACR
             2010 classification criteria of RA or modified New York criteria of Ankylosing
             spondylitis or ASAS criteria of axial or peripheral SpA or CASPAR criteria of PsA

        Exclusion Criteria:

          -  Opposition of the patient

          -  Patients in emergency situation, persons deprived of their liberty, protected minors
             or adults.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clément Prati, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Besançon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucine Vuitton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charline Vauchy, PhD</last_name>
    <phone>0381218875</phone>
    <email>cvauchy@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stéphanie François</last_name>
    <email>sfrancois@chu-besançon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charline Vauchy</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charline Vauchy, PhD</last_name>
      <email>cvauchy@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Clément Prati, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucine Vuitton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

